Senti Bio Joins Webull Corporate Connect Service Platform
Senti Biosciences (NASDAQ: SNTI), a clinical-stage biotechnology company developing next-generation cell and gene therapies, has announced its participation in the Webull Corporate Connect Service (CCS) platform. The company, which is advancing off-the-shelf CAR-NK cell therapy programs for oncology indications with its lead candidate SENTI-202 in clinical development for acute myeloid leukemia (AML), aims to enhance transparency and communication with shareholders through this new platform.
Through Webull CCS, Senti Bio will share corporate content including company news, earnings reports, product updates, and presentations. CEO Timothy Lu emphasized the company's commitment to maintaining effective communication with shareholders and building market awareness as they continue their clinical execution.
Senti Biosciences (NASDAQ: SNTI), una compagnia biotecnologica in fase clinica che sviluppa terapie cellulari e geniche di nuova generazione, ha annunciato la sua partecipazione alla Webull Corporate Connect Service (CCS) platform. L'azienda, che sta avanzando programmi di terapia CAR-NK pronti all'uso per indicazioni oncologiche con il suo candidato principale SENTI-202 in sviluppo clinico per la leucemia mieloide acuta (AML), mira a migliorare la trasparenza e la comunicazione con gli azionisti attraverso questa nuova piattaforma.
Attraverso Webull CCS, Senti Bio condividerà contenuti aziendali tra cui notizie aziendali, rapporti sugli utili, aggiornamenti sui prodotti e presentazioni. Il CEO Timothy Lu ha sottolineato l'impegno dell'azienda a mantenere una comunicazione efficace con gli azionisti e a costruire consapevolezza di mercato mentre continuano la loro esecuzione clinica.
Senti Biosciences (NASDAQ: SNTI), una empresa biotecnológica en etapa clínica que desarrolla terapias celulares y genéticas de nueva generación, ha anunciado su participación en la Webull Corporate Connect Service (CCS) platform. La compañía, que está avanzando en programas de terapia CAR-NK listos para usar para indicaciones oncológicas con su candidato principal SENTI-202 en desarrollo clínico para leucemia mieloide aguda (AML), busca mejorar la transparencia y la comunicación con los accionistas a través de esta nueva plataforma.
A través de Webull CCS, Senti Bio compartirá contenido corporativo que incluye noticias de la empresa, informes de ganancias, actualizaciones de productos y presentaciones. El CEO Timothy Lu enfatizó el compromiso de la empresa de mantener una comunicación efectiva con los accionistas y de aumentar la conciencia del mercado mientras continúan con su ejecución clínica.
Senti Biosciences (NASDAQ: SNTI), 차세대 세포 및 유전자 치료제를 개발하는 임상 단계의 생명공학 회사가 Webull Corporate Connect Service (CCS) platform에 참여한다고 발표했습니다. 이 회사는 급성 골수성 백혈병(AML)을 위한 임상 개발 중인 주요 후보인 SENTI-202와 함께 종양학 적응증에 대한 즉시 사용 가능한 CAR-NK 세포 치료 프로그램을 진행하고 있으며, 이 새로운 플랫폼을 통해 주주와의 투명성과 소통을 강화하는 것을 목표로 하고 있습니다.
Webull CCS를 통해 Senti Bio는 회사 뉴스, 수익 보고서, 제품 업데이트 및 프레젠테이션을 포함한 기업 콘텐츠를 공유할 것입니다. CEO Timothy Lu는 회사가 주주와의 효과적인 소통을 유지하고 임상 실행을 계속하는 동안 시장 인식을 구축하는 데 헌신하고 있음을 강조했습니다.
Senti Biosciences (NASDAQ: SNTI), une entreprise de biotechnologie en phase clinique développant des thérapies cellulaires et géniques de nouvelle génération, a annoncé sa participation à la Webull Corporate Connect Service (CCS) platform. L'entreprise, qui progresse avec des programmes de thérapie CAR-NK prêts à l'emploi pour des indications oncologiques avec son candidat principal SENTI-202 en développement clinique pour la leucémie myéloïde aiguë (AML), vise à améliorer la transparence et la communication avec les actionnaires grâce à cette nouvelle plateforme.
Grâce à Webull CCS, Senti Bio partagera des contenus d'entreprise, y compris des nouvelles de l'entreprise, des rapports de bénéfices, des mises à jour de produits et des présentations. Le PDG Timothy Lu a souligné l'engagement de l'entreprise à maintenir une communication efficace avec les actionnaires et à renforcer la sensibilisation au marché alors qu'ils poursuivent leur exécution clinique.
Senti Biosciences (NASDAQ: SNTI), ein biopharmazeutisches Unternehmen in der klinischen Phase, das zelluläre und genbasierte Therapien der nächsten Generation entwickelt, hat seine Teilnahme an der Webull Corporate Connect Service (CCS) platform angekündigt. Das Unternehmen, das Programme zur CAR-NK-Zelltherapie für onkologische Indikationen mit seinem Hauptkandidaten SENTI-202, der sich in der klinischen Entwicklung für akute myeloische Leukämie (AML) befindet, vorantreibt, zielt darauf ab, die Transparenz und Kommunikation mit den Aktionären über diese neue Plattform zu verbessern.
Über Webull CCS wird Senti Bio Unternehmensinhalte wie Unternehmensnachrichten, Gewinnberichte, Produktupdates und Präsentationen teilen. CEO Timothy Lu betonte das Engagement des Unternehmens, eine effektive Kommunikation mit den Aktionären aufrechtzuerhalten und das Marktbewusstsein zu stärken, während sie ihre klinische Umsetzung fortsetzen.
- Enhanced investor communication and transparency through new Webull CCS platform
- Lead candidate SENTI-202 advancing in clinical development for AML treatment
- None.
Company advancing off-the-shelf CAR-NK cell therapy programs for oncology indications with lead candidate, SENTI-202, in clinical development for the treatment of acute myeloid leukemia (AML)
Connect with the Company on Webull here
SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it is now participating on the Webull Corporate Connect Service (CCS) platform.
Senti Bio’s portal on the Webull CCS aims to provide an additional line of communication for shareholders and interested investors and to enhance transparency with its growing shareholder base. Through Webull, the Company will release notifications regarding corporate content, such as company news, earnings reports, product news, presentations, and more.
“As we continue to execute on the clinical front, maintaining effective and transparent communication with our shareholders remains a priority. We believe that building market awareness and increasing visibility among investors plays a key role in our overall communications. The Webull platform, in addition to our established corporate social channels and investor relations program, provides another valuable avenue for us to connect with our investors, and keep them up to date with the latest Company news and progress. We are excited for the year ahead and remain committed to generating value in the near and long term for all stakeholders,” says Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio.
To stay up to date on Senti Bio’s recent developments on the Webull Corporate Connect Services Platform, current Webull users can follow SNTI from the app on their smartphone or table device. To download the app and register for your free Webull account, visit www.webull.com/trading-platforms.
Others can access the Company’s information on Webull here.
About Webull Financial
Webull Financial is a leading digital investment platform registered with the Securities and Exchange Commission (SEC), as well as a member of both the Securities Investor Protection Corporation (SIPC) and the Financial Industry Regulatory Authority (FINRA). Webull serves millions of users around the world, working to connect investors with companies globally.
About Senti Bio
Senti Bio is a clinical-stage biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging a synthetic biology platform called Gene Circuits to create therapies with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells and control the expression of drugs even after administration. Senti Bio’s wholly-owned pipeline includes off-the-shelf CAR-NK cells, outfitted with Gene Circuits, to target challenging liquid and solid tumor indications. Senti Bio’s lead program SENTI-202, a Logic Gated CD33 and/or FLT3-targeting hematologic cancer therapeutic candidate, demonstrated MRD-negative complete remissions in 2 of 3 patients in initial clinical data as of September 19, 2024, with 6+ month durability as of March 20, 2025. Senti Bio has also preclinically demonstrated that its Gene Circuits can function in T cells, for example Logic Gates that enable selective targeting of solid tumors. Additionally, Senti Bio has preclinically demonstrated the potential breadth of Gene Circuits in other cell and gene therapy modalities, diseases outside of oncology, and continues to advance these capabilities through partnerships.
Forward-Looking Statements
This press release contains certain statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally are identified by the words “believe,” “could,” “predict,” “continue,” “ongoing,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” “forecast,” “seek,” “target” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations of Senti Bio’s management and assumptions, whether or not identified in this document, and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding future events, including the success of our future clinical development and ability to create shareholder value. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Senti Bio. Many factors could cause actual future results to differ materially from the forward-looking statements in this document, including but not limited to: (i) changes in domestic and foreign business, market, financial, political and legal conditions, (ii) changes in the competitive and highly regulated industries in which Senti Bio operates, variations in operating performance across competitors, changes in laws and regulations affecting Senti Bio’s business, (iii) the ability to implement business plans, forecasts and other expectations, (iv) the risk of downturns and a changing regulatory landscape in Senti Bio’s highly competitive industry, (v) risks relating to the uncertainty of any projected financial information with respect to Senti Bio, (vi) risks related to uncertainty in the timing or results of Senti Bio’s clinical trial initiation and the progress of clinical trials, patient enrollment, and GMP manufacturing activities, (vii) Senti Bio’s dependence on fourth parties in connection with clinical trial startup, clinical studies, and GMP manufacturing activities, (viii) risks related to delays and other impacts from macroeconomic and geopolitical events, increasing rates of inflation and rising interest rates on business operations, (ix) risks related to the timing and utilization of Senti Bio’s grant from CIRM and net proceeds of the PIPE financing, and (x) the success of any future research and development efforts by Senti Bio. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Senti Bio’s most recent Quarterly Report on Form 10-Q, filed with the U.S. Securities and Exchange Commission (“SEC”), and other documents filed by Senti Bio from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements in this document. There may be additional risks that Senti Bio does not presently know, or that Senti Bio currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements in this document. Forward-looking statements speak only as of the date they are made. Senti Bio anticipates that subsequent events and developments may cause Senti Bio’s assessments to change. Except as required by law, Senti Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com
FAQ
What is SENTI-202 and what condition is it targeting?
How will SNTI's participation in Webull CCS benefit shareholders?
What type of technology platform does Senti Bio (SNTI) use for its therapies?
Where can investors access Senti Bio's (SNTI) information on Webull?
